Patients bearing primary ER+ breast tumors which exhibit a protein expression/phosphorylation signature of PI3K activation, as determined using reverse-phase protein arrays (RPPA), have a shorter recurrence-free survival (Miller et al., 2010). The gene discussed is ESR1; the disease is breast neoplasm.